A 42-year-old man presents to the emergency department with sudden-onset shortness of brea… — USMLE Step 3

A 42-year-old man presents to the emergency department with sudden-onset shortness of breath and right-sided pleuritic chest pain. He has a history of focal onset seizures, which have been well controlled on carbamazepine for the past five years. Vital signs are temperature $37.1^\circ\text{C}$ ( $98.8^\circ\text{F}$ ), blood pressure $132/84\text{ mm Hg}$ , heart rate $105/\text{min}$ , respiratory rate $20/\text{min}$ , and oxygen saturation $95\%$ on room air. Physical examination reveals clear lungs and a swollen, tender right calf. A computed tomography pulmonary angiogram reveals a segmental pulmonary embolism in the right lower lobe. Laboratory studies reveal a serum creatinine of $0.9\text{ mg/dL}$ and normal hepatic function. Which of the following is the most appropriate pharmacologic intervention for this patient?

A
Initiate apixaban monotherapy
B
Administer intravenous alteplase
C
Initiate enoxaparin and transition to dabigatran
D
Initiate rivaroxaban and monitor anti-factor Xa levels
Initiate low-molecular-weight heparin and transition to warfarinCevap

Cevap

Initiate low-molecular-weight heparin and transition to warfarin

The correct intervention is to initiate a low-molecular-weight heparin and transition to warfarin. This patient has a hemodynamically stable pulmonary embolism. While direct oral anticoagulants (DOACs) are typically first-line, this patient is taking carbamazepine, a strong inducer of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). DOACs (e.g., apixaban, rivaroxaban) rely heavily on these pathways for metabolism and transport. Coadministration with strong inducers leads to significantly decreased DOAC plasma concentrations, increasing the risk of recurrent thromboembolism. Because warfarin dosing is individualized and titrated to an objective measure (the International Normalized Ratio, or INR), it can be safely used in patients on CYP inducers by adjusting the dose to maintain therapeutic efficacy.

Adım Adım Çözüm

Diagnose the acute condition based on clinical and radiographic findings.

The patient has a deep vein thrombosis and a hemodynamically stable pulmonary embolism.

Tender/swollen calf indicates DVT, and the CT angiogram confirms a segmental PE with stable vital signs (normotension).

Determine the standard first-line therapy for the acute condition.

Direct oral anticoagulants (DOACs) such as apixaban or rivaroxaban are typically first-line for hemodynamically stable venous thromboembolism.

DOACs are preferred over warfarin in the general population due to ease of use and lower bleeding risk.

Review the patient's medication list for interactions that contraindicate standard therapy.

The patient is taking carbamazepine, a strong inducer of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp).

DOACs are heavily metabolized by CYP3A4 and are substrates of P-gp. Coadministration with strong inducers leads to significantly decreased DOAC plasma concentrations and therapeutic failure.

Select the safest alternative pharmacologic intervention.

Initiate a low-molecular-weight heparin (LMWH) bridge to a titratable vitamin K antagonist (warfarin).

Warfarin dosing is individualized and titrated to an objective measure (the International Normalized Ratio). The dose can be safely increased to maintain therapeutic efficacy despite the presence of CYP inducers.

Anahtar Kavram

Patients requiring anticoagulation who are taking strong CYP3A4 and P-glycoprotein inducers (e.g., carbamazepine, rifampin, phenytoin) should not receive direct oral anticoagulants (DOACs) due to the risk of subtherapeutic levels; they require a heparin bridge to a titratable vitamin K antagonist (warfarin).

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru